Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria

Abstract

Tigecycline, given at the range of administered doses as salvage therapy and in combination with other antimicrobial agents, seemed to be well tolerated in a series of mainly critically ill pediatric patients and demonstrated relatively good clinical response in nonbacteremic patients.

Effectiveness of tigecycline in the treatment of infections caused by carbapenem‐resistant gram‐negative bacteria in pediatric liver transplant recipients: A retrospective study

“…However, off‐label use of TGC is widely adopted in critically ill adults, especially for infections caused by MDR/XDR pathogen . In real‐world clinical practice, successful cases are also reported for off‐label use of TGC in children, especially for infections caused by MDR/XDR bacteria . Pediatricians usually prescribe TGC as salvage therapy in serious infections.…”

“…9,10 In real-world clinical practice, successful cases are also reported for off-label use of TGC in children, especially TA B L E 2 Susceptibility testing results of K pneumoniae (n = 9) and A baumannii (n = 4) isolates to antimicrobial agents for infections caused by MDR/XDR bacteria. [11][12][13] Pediatricians usually prescribe TGC as salvage therapy in serious infections.…”

“…Thirteen children (6 males) with a median age of 8 (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) ceived TGC for at least 3 days (6 doses) as salvage therapy, and no patient was excluded. The average stay in ICU was 12.9 ± 11.9 days (range 3-37 days).…”

Tigecycline Use in Neonates: 5-Year Experience of a Tertiary Center

“…Almost all of the available data regarding the use of tigecycline in infants and children younger than 8 years derive from small case series collected retrospectively. [3][4][5][6][7]10 Although optimal dosage has not been defined, the usual dose reported in different case series ranged from 1 to 2 mg/kg every 12 hours. 1 In a case report of 12-month old liver transplant recipient with XDR Acinetobacter baumannii bacteremia, it was found that a dose of 1 mg/kg every 12 hours (without loading dose) provided similar drug exposure (area under the curve, AUC) with adult and children aged 8 to 11 years old.…”

“…1,2 The off-label use of tigecycline to treat serious infections (blood stream infections, urinary tract infections, nosocomial pneumonia, or meningitis) has been reported in the pediatric age group. [3][4][5][6][7] The majority of patients in these clinical series were beyond infancy, and it was stated that tigecycline was generally well tolerated except for gastrointestinal adverse events (nausea, vomiting, diarrhea, acute pancreatitis), prolonged coagulation times, and mild increase of transaminases. [3][4][5][6]8 However, there is only scant information on tigecycline use in newborn infants.…”